Deciphering the Potential Role of Post-translational Modifications of Histones in Gastrointestinal Cancers: a Proteomics-based Review with Therapeutic Challenges and Opportunities

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Nov 5

PMID 39497715

Authors

Reyhaneh Farrokhi Yekta

Masoumeh Farahani

Mehdi Koushki

Nasrin Amiri-Dashatan

Affiliations

Soon will be listed here.

Abstract

Oncogenesis is a complex and multi-step process, controlled by several factors including epigenetic modifications. It is considered that histone modifications are critical components in the regulation of gene expression, protein functions, and molecular interactions. Dysregulated post-translationally modified histones and the related enzymatic systems are key players in the control of cell proliferation and differentiation, which are associated with the onset and progression of cancers. The most of traditional investigations on cancer have focused on mutations of oncogenes and tumor suppressor genes. However, increasing evidence indicates that epigenetics, especially histone post-translational modifications (PTMs) play important roles in various cancer types. Mass spectrometry-based proteomic approaches have demonstrated tremendous potential in PTMs profiling and quantitation in different biological systems. In this paper, we have made a proteomics-based review on the role of histone modifications involved in gastrointestinal cancers (GCs) tumorigenesis processes. These alterations function not only as diagnostic or prognostic biomarkers for GCs, but a deeper comprehension of the epigenetic regulation of GCs could facilitate the treatment of this prevalent malignancy through the creation of more effective targeted therapies.

References

Zang W, Hu Y, Qian C, Feng Y, Liu J, Yang J . HDAC4 promotes the growth and metastasis of gastric cancer via autophagic degradation of MEKK3. Br J Cancer. 2022; 127(2):237-248. PMC: 9296555. DOI: 10.1038/s41416-022-01805-7. View

Pathak S, Basu S, Bhattacharyya A, Pathak S, Banerjee A, Basu J . TLR4-dependent NF-kappaB activation and mitogen- and stress-activated protein kinase 1-triggered phosphorylation events are central to Helicobacter pylori peptidyl prolyl cis-, trans-isomerase (HP0175)-mediated induction of IL-6 release from.... J Immunol. 2006; 177(11):7950-8. DOI: 10.4049/jimmunol.177.11.7950. View

Karczmarski J, Rubel T, Paziewska A, Mikula M, Bujko M, Kober P . Histone H3 lysine 27 acetylation is altered in colon cancer. Clin Proteomics. 2014; 11(1):24. PMC: 4071346. DOI: 10.1186/1559-0275-11-24. View

Yun M, Wu J, Workman J, Li B . Readers of histone modifications. Cell Res. 2011; 21(4):564-78. PMC: 3131977. DOI: 10.1038/cr.2011.42. View

Xing J, Zhang A, Du Y, Fang M, Minze L, Liu Y . Identification of poly(ADP-ribose) polymerase 9 (PARP9) as a noncanonical sensor for RNA virus in dendritic cells. Nat Commun. 2021; 12(1):2681. PMC: 8113569. DOI: 10.1038/s41467-021-23003-4. View

Mulero-Navarro S, Esteller M . Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol. 2008; 68(1):1-11. DOI: 10.1016/j.critrevonc.2008.03.001. View

Darieva Z, Webber A, Warwood S, Sharrocks A . Protein kinase C coordinates histone H3 phosphorylation and acetylation. Elife. 2015; 4:e09886. PMC: 4714974. DOI: 10.7554/eLife.09886. View

Hardwicke M, Oleykowski C, Plant R, Wang J, Liao Q, Moss K . GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther. 2009; 8(7):1808-17. DOI: 10.1158/1535-7163.MCT-09-0041. View

Paredes S, Villanova L, Chua K . Molecular pathways: emerging roles of mammalian Sirtuin SIRT7 in cancer. Clin Cancer Res. 2014; 20(7):1741-6. PMC: 3980586. DOI: 10.1158/1078-0432.CCR-13-1547. View

10.

Lau P, Cheung P . Histone code pathway involving H3 S28 phosphorylation and K27 acetylation activates transcription and antagonizes polycomb silencing. Proc Natl Acad Sci U S A. 2011; 108(7):2801-6. PMC: 3041124. DOI: 10.1073/pnas.1012798108. View

11.

Xu J, Guan X, Jia X, Li H, Chen R, Lu Y . In-depth Profiling and Quantification of the Lysine Acetylome in Hepatocellular Carcinoma with a Trapped Ion Mobility Mass Spectrometer. Mol Cell Proteomics. 2022; 21(8):100255. PMC: 9294201. DOI: 10.1016/j.mcpro.2022.100255. View

12.

Marmorstein R, Zhou M . Writers and readers of histone acetylation: structure, mechanism, and inhibition. Cold Spring Harb Perspect Biol. 2014; 6(7):a018762. PMC: 4067988. DOI: 10.1101/cshperspect.a018762. View

13.

Cherrington B, Zhang X, McElwee J, Morency E, Anguish L, Coonrod S . Potential role for PAD2 in gene regulation in breast cancer cells. PLoS One. 2012; 7(7):e41242. PMC: 3404060. DOI: 10.1371/journal.pone.0041242. View

14.

Stewart M, Li J, Wong J . Relationship between histone H3 lysine 9 methylation, transcription repression, and heterochromatin protein 1 recruitment. Mol Cell Biol. 2005; 25(7):2525-38. PMC: 1061631. DOI: 10.1128/MCB.25.7.2525-2538.2005. View

15.

Dai Q, Zhang C, Yuan Z, Sun Q, Jiang Y . Current discovery strategies for hepatocellular carcinoma therapeutics. Expert Opin Drug Discov. 2019; 15(2):243-258. DOI: 10.1080/17460441.2020.1696769. View

16.

Seeler J, Dejean A . SUMO and the robustness of cancer. Nat Rev Cancer. 2017; 17(3):184-197. DOI: 10.1038/nrc.2016.143. View

17.

Choi C, Lee G, Son A, Yoo G, Yu J, Park H . Downregulation of Mcl-1 by Panobinostat Potentiates Proton Beam Therapy in Hepatocellular Carcinoma Cells. Cells. 2021; 10(3). PMC: 7999709. DOI: 10.3390/cells10030554. View

18.

Ono S, Oue N, Kuniyasu H, Suzuki T, Ito R, Matsusaki K . Acetylated histone H4 is reduced in human gastric adenomas and carcinomas. J Exp Clin Cancer Res. 2002; 21(3):377-82. View

19.

Li Y, Seto E . HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med. 2016; 6(10). PMC: 5046688. DOI: 10.1101/cshperspect.a026831. View

20.

Di Cerbo V, Schneider R . Cancers with wrong HATs: the impact of acetylation. Brief Funct Genomics. 2013; 12(3):231-43. DOI: 10.1093/bfgp/els065. View